Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Psoriasis drug safety under the microscope: brodalumab vs alternatives

NCT ID NCT03254667

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times

Summary

This study tracks 3,500 adults with moderate-to-severe psoriasis to compare the long-term safety of brodalumab against other standard treatments. Participants are already taking these medications as part of their normal care. The main goal is to see if brodalumab is linked to a higher risk of cancer compared to other biologic drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Registry

    Bridgewater, New Jersey, 08807, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

brodalumab

What this could lead to

If successful, this study could provide real-world safety data to help doctors choose the best psoriasis treatment for their patients.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It does not test a new treatment or aim for a cure.

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.